THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to ...
Almost all (95%) Medicare drug plans cover Repatha. This includes standalone Part D prescription drug plans and Medicare Advantage plans that include prescription drug coverage. Repatha is a brand ...
A series of abstracts also made the case for serious gaps in GLP-1 treatment, which Amgen figures its investigational MariTide could fill. (Amgen, American Diabetes Association) As Amgen strives to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results